27313614|t|Frequency of BCR-ABL Transcript Types in Syrian CML Patients
27313614|a|Background. In Syria, CML patients are started on tyrosine kinase inhibitors (TKIs) and monitored until complete molecular response is achieved. BCR-ABL mRNA transcript type is not routinely identified, contrary to the recommendations. In this study we aimed to identify the frequency of different BCR-ABL transcripts in Syrian CML patients and highlight their significance on monitoring and treatment protocols. Methods. CML patients positive for BCR-ABL transcripts by quantitative RT-PCR were enrolled. BCR-ABL transcript types were investigated using a home-made PCR method that was adapted from published protocols and optimized. The transcript types were then confirmed using a commercially available research kit. Results. Twenty-four transcripts were found in 21 patients. The most common was b2a2, followed by b3a2, b3a3, and e1a3 present solely in 12 (57.1%), 3 (14.3%), 2 (9.5%), and 1 (4.8%), respectively. Three samples (14.3%) contained dual transcripts. While b3a2 transcript was apparently associated with warning molecular response to imatinib treatment, b2a2, b3a3, and e1a3 transcripts collectively proved otherwise (P = 0.047). Conclusion. It might be advisable to identify the BCR-ABL transcript type in CML patients at diagnosis, using an empirically verified method, in order to link the detected transcript with the clinical findings, possible resistance to treatment, and appropriate monitoring methods.
27313614	13	20	BCR-ABL	T028	C1835417
27313614	21	31	Transcript	T114	C1519595
27313614	41	47	Syrian	T098	C0337819
27313614	48	51	CML	T191	C0023473
27313614	52	60	Patients	T101	C0030705
27313614	76	81	Syria	T083	C0039138
27313614	83	86	CML	T191	C0023473
27313614	87	95	patients	T101	C0030705
27313614	111	137	tyrosine kinase inhibitors	T044	C2757011
27313614	139	143	TKIs	T044	C2757011
27313614	174	192	molecular response	T033	C4054479
27313614	206	213	BCR-ABL	T028	C1835417
27313614	214	218	mRNA	T114,T123	C0035696
27313614	219	229	transcript	T114	C1519595
27313614	280	295	recommendations	T078	C0034866
27313614	359	366	BCR-ABL	T028	C1835417
27313614	367	378	transcripts	T114	C1519595
27313614	382	388	Syrian	T098	C0337819
27313614	389	392	CML	T191	C0023473
27313614	393	401	patients	T101	C0030705
27313614	453	472	treatment protocols	T061	C0040808
27313614	483	486	CML	T191	C0023473
27313614	487	495	patients	T101	C0030705
27313614	496	504	positive	T033	C1446409
27313614	509	516	BCR-ABL	T028	C1835417
27313614	517	528	transcripts	T114	C1519595
27313614	532	544	quantitative	T081	C0392762
27313614	545	551	RT-PCR	T063	C0599161
27313614	567	574	BCR-ABL	T028	C1835417
27313614	575	585	transcript	T114	C1519595
27313614	597	609	investigated	T169	C1292732
27313614	628	631	PCR	T063	C0032520
27313614	661	680	published protocols	T170	C0936005
27313614	685	694	optimized	T052	C2698650
27313614	700	710	transcript	T114	C1519595
27313614	768	780	research kit	T074	C0812225
27313614	803	814	transcripts	T114	C1519595
27313614	832	840	patients	T101	C0030705
27313614	862	866	b2a2	T114,T123	C3840354
27313614	880	884	b3a2	T114,T123	C3840353
27313614	886	890	b3a3	T114	C1519595
27313614	896	900	e1a3	T114	C1519595
27313614	1017	1028	transcripts	T114	C1519595
27313614	1036	1051	b3a2 transcript	T114,T123	C3840353
27313614	1067	1082	associated with	T080	C0332281
27313614	1091	1109	molecular response	T033	C4054479
27313614	1113	1121	imatinib	T109,T121	C0935989
27313614	1122	1131	treatment	T061	C0087111
27313614	1133	1137	b2a2	T114,T123	C3840354
27313614	1139	1143	b3a3	T114	C1519595
27313614	1149	1165	e1a3 transcripts	T114	C1519595
27313614	1259	1266	BCR-ABL	T028	C1835417
27313614	1267	1277	transcript	T114	C1519595
27313614	1286	1289	CML	T191	C0023473
27313614	1290	1298	patients	T101	C0030705
27313614	1381	1391	transcript	T114	C1519595
27313614	1401	1418	clinical findings	T170	C0455712
27313614	1429	1439	resistance	T169	C4281815
27313614	1443	1452	treatment	T061	C0087111
27313614	1470	1488	monitoring methods	T058	C1283169